Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa

Clinical Infectious Diseases

Volumn 28, Issue 5, 1999, Pages 1128-1133

  Harris, Anthony ^a,b   Torres Viera, Carlos ^a   Venkataraman, Lata ^a   DeGirolami, Paola ^a   Samore, Matthew ^a   Carmeli, Yehuda ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; PIPERACILLIN; TICARCILLIN; TOBRAMYCIN;

ADULT; AGED; ARTICLE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; ENTEROCUTANEOUS FISTULA; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; LENGTH OF STAY; LUNG INFECTION; MALE; MORTALITY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PULSED FIELD GEL ELECTROPHORESIS; RETROSPECTIVE STUDY; SOFT TISSUE INFECTION; TREATMENT OUTCOME;

EID: 0032938913     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/514760     Document Type: Article

References (27)

1. 1. Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 1998; 11:57-80.
2. 2. Hejazi A, Falkiner FR. Serratia marcescens. J Clin Microbiol 1997; 46: 903-12.
3. 3. Bergogne-Berezin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996; 9:148-65.
4. 4. Iyobe S, Hirai K, Hashimoto H. Drug resistance of Pseudomonas aeruginosa with special reference to new quinolones. Antibiot Chemother 1991; 44:209-14.
5. 5. Burwen DR, Banerjee SN, Gaynes R. Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. J Infect Dis 1994; 170:1622-5.
6. 6. Basustaoglu AC, Gun H, Saracli MA, Baysallar M, Haznedaroglu T. Development of resistance to imipenem among nosocomial isolates of Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis 1995; 14: 469-70.
7. 7. Quinn JP, Dudek EJ, DiVincenzo CA, Lucks DA, Lerner SA. Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections. J Infect Dis 1986; 154:289-94.
8. 8. Fink MP, Snydman DR, Niederman MS, et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenemcilastin. Antimicrob Agents Chemother 1994; 38:547-57.
9. 9. Pechere JC, Vladoianu IR. Development of resistance during ceftazidime and cefipime therapy in a murine peritonitis model. J Antimicrob Chemother 1992; 29:563-73.
10. 10. Carmeli Y, Troillet N, Eliopoulos G, Samore M. Emergence of antibiotic resistant Pseudomonas aeruginosa (PA): the association with various antipseudomonal agents [abstract no 435]. Clin Infect Dis 1997; 25:435.
11. 11. Troillet N, Jaccard C, Commeta A, Bille A, Glauser MP. Emergence of resistant Pseudomonas aeruginosa during imipenem vs. piperacillin-tazobactam therapy [abstract no P737]. In: Program and abstracts of the 8th European Congress of Clinical Microbiology and Infectious Diseases (Lausanne, Switzerland). Oslo: The European Society of Clinical Microbiology and Infectious Diseases, 1997.
12. 12. Iten A, Cometta A, Moreillon P, Eggimann P, Siegrist H, Francioli P. Addition of netilmicin to imipenem does not prevent the emergence of imipenem-resistance during treatment [abstract no C112]. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology, 1996.
13. 13. Manian FA, Meyer L, Jenne J, Owen A, Taff T. Loss of antimicrobial susceptibility in aerobic gram-negative bacilli repeatedly isolated from patients in intensive-care units. Infect Control Hosp Epidemiol 1996; 17:222-6.
14. 14. Milatovic D, Braveny I. Development of resistance during antibiotic therapy. Eur J Clin Microbiol Infect Dis 1987; 6:234-44.
15. 15. Carmeli Y, Troillet N, Karchmer AW, Samore MH. Pseudomonas aeruginosa: health and economic impact of antibiotic resistance and emergence of resistance. Arch Intern Med (in press).
16. 16. Aris RM, Gilligan PH, Neuringer IP, Gott KK, Rea J, Yankaskas JR. The effects of panresistant bacteria in cystic fibrosis patients on lung transplant outcome. Am J Respir Crit Care Med 1997; 155:1699-704.
17. 17. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16:128-40.
18. 18. Maslow JN, Slutsky AM, Arbeit RD. The application of pulsed field gel electrophoresis to molecular epidemiology. In: Persing DH, Smith TF, Tenover FC, White TJ, eds. Diagnostic molecular microbiology: principles and applications. Washington DC: American Society for Microbiology, 1994.
19. 19. D'Agata E, Venkataraman L, DeGirolami P, Samore M. Molecular epidemiology of ceftazidime-resistant gram-negative bacilli in a non-outbreak setting. J Clin Microbiol 1997; 35:2602-5.
20. 20. Tenover FC, Arbeit RD, Goering RV, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995; 33:2233-9.
21. 21. Mouton JW, denHollander JG, Horrevorts AM. Emergence of antibiotic resistance amongst Pseudomonas aeruginosa isolates from patients with cystic fibrosis. J Antimicrob Chemother 1993; 31:919-26.
22. 22. Struelens MJ, Schwam V, Deplano A, Baran D. Genome macrorestriction analysis of diversity and variability of pseudomonas aeruginosa strains infecting cystic fibrosis patients. J Clin Microbiol 1993; 31:2320-6.
23. 23. Bosso JA, Allan JE, Matsen JM. Changing susceptibility of Pseudomonas aeruginosa isolates from cystic fibrosis patients with clinical use of newer antibiotics. Antimicrob Agents Chemother 1989; 33:526-8.
24. 24. Krasinski KM. Virulence versus resistance. Bull NY Acad Med 1987; 63: 237-52.
25. 25. Gillespie SH, McHugh TD. The biological cost of antimicrobial resistance. Trends Microbiol 1997; 5:337-9.
26. 26. Livermore DM. Bacterial resistance to carbapenems. Adv Exp Med Biol 1995; 390:25-47.
27. 27. Saiman L, Mehar F, Niu WW, et al. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infect Dis 1996; 23:532-7.